Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Subcutaneous Doses of LY2127399 in Relapsing-Remitting Multiple Sclerosis
2008-007459-28Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing LY2127399 arm with Placebo arm (2 arms). Primary endpoint: Cumulative total gadolinium-enhancing MRI lesions. Started Dec 2008; status: completed.
02
Drugs
tabalumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-007459-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007459-28.